Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review and meta-analysis

Urology

Volumn 77, Issue 1, 2011, Pages 123-129

  Liu, Liangren ^a   Zheng, Shuo ^a   Han, Ping ^a   Wei, Qiang ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SILDENAFIL; TADALAFIL; VARDENAFIL;

ARTICLE; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; EMBASE; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MEDLINE; META ANALYSIS; PENIS ERECTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESIDUAL URINE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINE FLOW RATE;

HUMANS; MALE; PHOSPHODIESTERASE 5 INHIBITORS; PROSTATIC HYPERPLASIA; PROSTATISM;

EID: 78650923653     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.07.508     Document Type: Article

References (28)

1. J.C. Nickel Inflammation and benign prostatic hyperplasia Urol Clin North Am 35 2008 109 115
2. A. Tsertsvadze, H.A. Fink, and F. Yazdi Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis Ann Intern Med 151 2009 650 661
3. C. Wang Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia Curr Opin Urol 20 2010 49 54
4. P. Wong, N. Lawrentschuk, and D.M. Bolton Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds Curr Opin Urol 19 2009 7 12
5. R. Rosen, J. Alrwein, and P. Boyle Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7) Eur Urol 44 2003 637 649
6. R.C. Rosen, J.T. Wei, S.E. Althof BPH Registry and Patient Survey Steering Committee Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry Urology 73 2009 562 566
7. K.T. McVary Erectile 7 and lower urinary tract symptoms secondary to BPH Eur Urol 47 2005 838 845
8. A.R. Jadad, R.A. Moore, and D. Carroll Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12
9. K.T. McVary, C.G. Roehrborn, and J.C. Kaminetsky Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia J Urol 177 2007 1401 1407
10. C.G. Roehrborn, K.T. McVary, and A. Elion-Mboussa Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study J Urol 180 2008 1228 1234
11. H. Porst, K.T. McVary, and F. Montorsi Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia Eur Urol 56 2009 727 735
12. G.A. Broderick, G.B. Brock, and C.G. Roehrborn Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction Urology 75 2010 1452 1458
13. C.G. Roehrborn, J.C. Kaminetsky, and S.M. Auerbach Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment BJU Int 105 2010 502 507
14. R. Dmochowski, C. Roehrborn, and S. Klise Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial J Urol 183 2010 1092 1097
15. C.G. Stief, H. Porst, and D. Neuser A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia Eur Urol 53 2008 1236 1244
16. K.T. McVary, J. Kamps, and G.D. Henry Sildenafil improves erectile function and urinary symptoms in men with erectile dysfunction and concomitant lower urinary tract symptoms (abstract) J Urol 175 2006 527
17. K.T. McVary, J. Kaufman, and J.M. Young Sildenafil citrate improves erectile function: a randomised double-blind trial with open-label extension Int J Clin Pract 61 2007 1843 1849
18. K.T. McVary, W. Monnig, and J.L. Camps Jr Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial J Urol 177 2007 1071 1077
19. K.T. McVary, R.L. Siegel, and M. Carlsson Sildenafil citrate improves erectile function and lower urinary tract symptoms independent of baseline body mass index or LUTS severity Urology 72 2008 575 579
20. American Urological Association (AUA) Benign Prostatic Hyperplasia (BPH) Guideline Update Panel Guideline on the management of benign prostatic hyperplasia (BPH) 2006 American Urological Association http://www.auanet.org/ guidelines/bph.cfm Accessed March 2008
21. K.A. Greco, and K.T. McVary The role of combination medical therapy in benign prostatic hyperplasia Int J Impot Res 20 suppl 3 2008 S33 S43
22. G. Untergasser, S. Madersbacher, and P. Berger Benign prostatic hyperplasia: age-related tissue-remodeling Exp Gerontol 40 2005 121 128
23. S. Filippi, A. Morelli, and P. Sandner Characterization and functional role of an androgen-dependent PDE5 activity in the bladder Endocrinology 148 2007 1019 1029
24. H. Tinel, B. Stelte-Ludwig, and J. Htter Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms BJU Int 98 2006 1259 1263
25. S. Oger, D. Behr-Roussel, and D. Gorny Combination of alfuzosin and tadalafil exerts an additive relaxant effect on human detrusor and prostatic tissues in vitro Eur Urol 57 2010 699 707
26. S. Uckert, M. Sormes, and G. Kedia Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue Urology 71 2008 526 530
27. S. Matsumoto, T. Hanai, and H. Uemura Effects of chronic treatment with vardenafil, a phosphodiesterase 5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model BJU Int 103 2009 987 990
28. M. Gacci, G. Del Popolo, and A. Macchiarella Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study J Urol 178 2007 2040 2043